4 Analysts Have This to Say About BridgeBio Pharma
Portfolio Pulse from Benzinga Insights
BridgeBio Pharma (NASDAQ:BBIO) has received positive analyst ratings in the last quarter, with an average price target of $47.25, indicating an upside from the current price of $31.07. The average price target has increased by 43.18% over the past month.
August 14, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma has received positive analyst ratings, indicating potential upside from its current price.
Analyst ratings are a significant factor in stock performance. The positive ratings and increased price target for BridgeBio Pharma suggest a potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100